期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 10, 期 6, 页码 587-593出版社
OXFORD UNIV PRESS
DOI: 10.1016/j.ejheart.2008.04.008
关键词
hawthorn; heart failure progression; Cralaegus Special Extract WS 1442; Crataegus oxycantha
资金
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061202] Funding Source: NIH RePORTER
- NCRR NIH HHS [M01-RR00042, M01 RR000042] Funding Source: Medline
- NHLBI NIH HHS [P50 HL061202-010002, P50 HL 061202 01] Funding Source: Medline
Aim: To examine whether hawthorn (Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients. Methods: We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6 months. The primary outcome was time to progression of HF (HF death, hospitarlisation, or sustained increase in diuretics) as assessed by log-rank tests and by Cox modelling. Results: Progression of HE occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients receiving CSE were 3.9 times (95% Cl= 1.1-13.7: p=0.035) more likely to experience HE progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI= 1.5, 26.5: p=0.01 1). In patients with LVEF <= 35%, those taking CSE were at significantly greater risk (3.2, 95% CI = 1.3, 8.3: p = 0.02) than the placebo group. Conclusions: CSE does not reduce heart failure progression in patients who have HE. CSE appears to increase the early risk of HE progression. (c) 2008 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据